$PFE

Explicit claim • strong conviction • basis: multiple relative

EPS projected per se Alpha $2.98. That brings a price to earnings ratio at under 10 at 9.33.

Explicit claim • strong conviction • basis: fair value gap

Valuation has never been very expensive for Pfizer when measuring on a forward price to earnings basis. It's trading at a forward PE of 9.6 right now and I would say this is the level the business deserves to be trading for. ... I also calculated a fair value for the stock using my discounted cash flow model and I came to the conclusion that the business is worth around $50 per share. The current market price is $28 and so I calculate considerable upside here for Pfizer stock of above 80%.

Explicit claim • strong conviction • basis: drawdown discount

Fizer's stock price is now sitting even lower today than it did before the pandemic ever even happened. ... Yet, their financials are much higher than they ever were back then, which makes absolutely zero sense.

Explicit claim • strong conviction • basis: explicit term

And at the exact same time, they're trading at what looks like a dirt cheap valuation. The average PE multiple over the last 3 years for them is about 10.7. Now, they're all the way down to just 8.7 times earnings.